These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21482493)

  • 1. Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
    Livi L; Meattini I; de Luca Cardillo C; Scotti V; Agresti B; Franzese C; Sanchez L; Nori J; Bertocci S; Cassani S; Bianchi S; Cataliotti L; Biti G
    J Chemother; 2011 Feb; 23(1):36-9. PubMed ID: 21482493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
    von Minckwitz G; Kümmel S; du Bois A; Eiermann W; Eidtmann H; Gerber B; Hilfrich J; Huober J; Costa SD; Jackisch C; Grasshoff ST; Vescia S; Skacel T; Loibl S; Mehta KM; Kaufmann M;
    Ann Oncol; 2008 Feb; 19(2):292-8. PubMed ID: 17846019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey J; Paterson A; Noel D; al-Tweigeri ; Janowska A; Delorme F; Riva A
    Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):25-7. PubMed ID: 9213324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
    Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
    Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
    Martín M; Lluch A; Seguí MA; Ruiz A; Ramos M; Adrover E; Rodríguez-Lescure A; Grosse R; Calvo L; Fernandez-Chacón C; Roset M; Antón A; Isla D; del Prado PM; Iglesias L; Zaluski J; Arcusa A; López-Vega JM; Muñoz M; Mel JR
    Ann Oncol; 2006 Aug; 17(8):1205-12. PubMed ID: 16766587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
    Vriens BE; Aarts MJ; de Vries B; van Gastel SM; Wals J; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Borm GF; Tjan-Heijnen VC;
    Eur J Cancer; 2013 Oct; 49(15):3102-10. PubMed ID: 23850450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
    Lambert-Falls R; Modugno S
    Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
    Langeberg WJ; Siozon CC; Page JH; Morrow PK; Chia VM
    Support Care Cancer; 2014 Aug; 22(8):2167-75. PubMed ID: 24652049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
    Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
    Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
    Liu MC; Demetri GD; Berry DA; Norton L; Broadwater G; Robert NJ; Duggan D; Hayes DF; Henderson IC; Lyss A; Hopkins J; Kaufman PA; Marcom PK; Younger J; Lin N; Tkaczuk K; Winer EP; Hudis CA;
    Cancer Treat Rev; 2008 May; 34(3):223-30. PubMed ID: 18234424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
    Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
    Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
    Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
    Puhalla S; Mrozek E; Young D; Ottman S; McVey A; Kendra K; Merriman NJ; Knapp M; Patel T; Thompson ME; Maher JF; Moore TD; Shapiro CL
    J Clin Oncol; 2008 Apr; 26(10):1691-7. PubMed ID: 18316792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
    Wolowacz SE; Cameron DA; Tate HC; Bagust A
    J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
    Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
    Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
    J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.